Professor Thomas Jaki and the city of Wuhan, China
A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus.
There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.
The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.
Professor Thomas Jaki, from the Medical and Pharmaceutical Statistics Research Unit in the Department of Mathematics and Statistics at Lancaster University, said the initial trial in Wuhan, China, investigated whether anti-viral drugs used to treat HIV would relieve the symptoms of COVID-19 – and started when there were less than 500 confirmed cases worldwide.
The trial saw 199 COVID-19 patients at Jin Yin-Tan Hospital treated either using standard of care or being given lopinavir–ritonavir. The results were published recently and showed enough promise that further, larger trials of the lopinavir–ritonavir treatment have now been established.
Specifically, the trial showed that patients who were randomly chosen to receive lopinavir–ritonavir appeared to improve faster. Meanwhile, among those patients who actually received lopinavir–ritonavir, the time to clinical improvement was significantly shorter than in patients receiving standard of care alone. At the same time acceptable safety levels were observed.
Professor Jaki said: “The results were quite encouraging, which has led to further studies taking place and I would expect to see these treatments to be introduced into routine care, in some cases, in the coming weeks.”
The findings from this study will also be considered as part of the forthcoming Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial. This will provide a trial platform to evaluate some of the approximately 30 treatments which are currently believed to have potential for treatment of COVID-19. The chief investigator for that trial is Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine at the University of Oxford – who was also part of the initial study in Wuhan.
Professor Jaki said the fact these studies were taking place during a medical emergency had seen a determination to move things forward at pace.
He added: “The astonishing thing about the RECOVERY trial is the speed with which it got off the ground, from the initial agreement being received from the Department of Health and Social Care it was just nine days before the first patient was recruited. That process would usually take between six and nine months.
“We have benefitted by learning from trials in China – keep it simple. RECOVERY uses a very short protocol and attempts to minimise burden on staff in hospitals which are overwhelmed, so we have tried to ensure data collection is simple. It is an important study and one which needs to be done quickly.
“This is one of the largest trials into treatments for COVID-19. There is a second large trial that is currently recruiting in the UK – REMAP-CAP – which is looking at impacts of treatments on severely ill patients, but both teams have worked together to ensure they will be able to learn as much as they can from both trials.
“This is unusual but a lot of the competitive nature of these things isn’t there at the moment. We all have the same goal.”
The RECOVERY trial has been classed as an Urgent Public Health Research Study. It is one of a round of projects to receive £10.5m as part of the £20m rapid research response funded by UK Research and Innovation, and by the Department of Health and Social Care through the National Institute for Health Research (NIHR).
Chief Medical Officer Professor Chris Whitty and NHS England Medical Director Professor Stephen Powis have written to NHS trusts in England asking them to fully support the new trial.
Professor Jaki is also one of the authors of an opinion piece published in the New England Medical Journal last week on an approach to clinical trials around large epidemics.
While the piece was predominantly written months before the coronavirus outbreak, it encourages greater collaboration between scientists and much of the advice is already being reflected in the World Health Organisation’s developing strategy.
Professor Jaki added: “This is the culmination of a conversation which started several years ago where the WHO recognised the necessity of pre-planning in the event of a disease outbreak.
“While it may sometimes feel like we are unprepared for incidents like the COVID-19 outbreak there is actually a co-ordinated global effort among scientists, and Lancaster plays its part in that.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 treatment
- One-dose J&J COVID-19 vaccine meets criteria as safe and effective, FDA report findson February 24, 2021 at 5:40 am
A key FDA committee meets Friday to review the one-dose COVID vaccine from J&J. Authorization for its use in the US is expected to swiftly follow.
- What the mink COVID-19 outbreaks taught us about pandemicson February 24, 2021 at 5:38 am
Denmark killed all its farmed mink last year, millions of animals, after a variant form of the novel coronavirus was detected circulating between mink and humans. New research has shown that many mink ...
- FDA finds one-dose J&J COVID-19 vaccine meets criteria as safe and effectiveon February 24, 2021 at 5:31 am
A key FDA committee meets Friday to review the one-dose COVID vaccine from J&J. Authorization for its use in the US is expected to swiftly follow.
- APAC Laser Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis - ResearchAndMarkets.comon February 24, 2021 at 5:30 am
The "Asia Pacific Laser Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's ...
- Promising Treatment for Covid-19 Enters Clinical Trials in Israeli Medical Centerson February 24, 2021 at 5:30 am
Researchers at two major medical centers in Israel, Rambam Medical Health Care Campus and Ziv Medical Center, have initiated a Phase 2 ...
Go deeper with Google Headlines on:
COVID-19 treatment
Go deeper with Bing News on:
Lopinavir–ritonavir
- Arbidol Hydrochloride Market Analysis Covering Size, Share, Growth, Trends and Upcoming Opportunities | By Kenneth Researchon February 24, 2021 at 5:18 am
Such factors are anticipated to drive the growth of the ARBIDOL HYDROCHLORIDE MARKET during the forecast period. Click Here to Download Sample Report >> Arbidol Hydrochloride is a Russia-made ...
- WHO clarifies on traditional medical treatment for Covid-19 after Patanjali's Coronil claimon February 21, 2021 at 5:01 am
WHO said it has 'not reviewed or certified the effectiveness of any traditional medicine for the treatment of Covid-19'.The clarification comes amid claims made by Baba Ramdev's Patanjali Ayurved that ...
- Lopinavir/Ritonavir-based Therapy Trumps Nevirapine-based Therapy for Women Previously Exposed to Single-dose Nevirapineon February 16, 2021 at 4:00 pm
The women were randomized to receive tenofovir/FTC plus either nevirapine or lopinavir/ritonavir. During a median follow-up of 74 months, the nevirapine group had a significantly higher rate of ...
- Repurposed Arthritis Drug Lifesaving for Severe Covid-19, UK Trial Findson February 12, 2021 at 5:20 am
The study has also helped rule out once promising treatments such as hydroxychloroquine and the HIV cocktail lopinavir-ritonavir. A widely used and cheap steroid treatment appears to be the first ...
- COVID-19: TCTMD’s Daily Dispatch for February Week 2on February 8, 2021 at 6:00 am
TCTMD’s Todd Neale recently explored the data surrounding the use of anticoagulation in different COVID-19 settings in a feature story. A spike in retail pharmacy sales of hydroxychloroquine, ...